Drug Profile
LY 309132
Latest Information Update: 07 Feb 2014
Price :
$50
*
At a glance
- Originator Eli Lilly and Company
- Class Antihyperlipidaemics; Insulins
- Mechanism of Action Ornithine decarboxylase stimulants; Phosphokinase stimulants; Tyrosine aminotransferase stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Diabetes mellitus